Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventional

PET Functional Imaging to Evaluate Cardiac Radiation Damage (EUCLID)

NCT ID: NCT05775939Sponsor: Thomas Jefferson UniversityLast updated: 2026-02-10

Summary

This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung or esophageal cancer. As part of the treatment for lung or esophageal cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, either increasing or decreasing the function. It is not known the consequences of this change nor is it known if doctors can detect the changes associated with the radiation. Sarcoidosis FDG positron emission tomography (PET)-computed tomography (CT) scans are a common way to image cardiac inflammation and myocardial viability. This study may help doctors image the heart before, during and after radiotherapy to monitor any changes.

Detailed description

PRIMARY OBJECTIVE: I. To characterize radiation-related functional imaging changes in the heart using sarcoidosis fludeoxyglucose F-18 (FDG) PET-CT imaging. SECONDARY OBJECTIVES: I. 1. To evaluate the ability of imaging changes in the heart to predict for overall survival (OS). II. To evaluate the ability of imaging changes in the heart to predict for cardiac toxicity. III. To evaluate the ability of imaging changes in the heart to predict for cardiac related death. EXPLORATORY OBJECTIVES: I. To evaluate radiation treatment planning strategies to reduce risk of cardiotoxicity. II. To determine the correlation between sarcoidosis FDG PET-CT scans and oncologic FDG PET-CT scans. OUTLINE: Patients undergo sarcoidosis FDG PET-CT of the heart before, during and, after radiotherapy. After completion of study treatment, patients are followed up at 12 and 24 months.

Arms & interventions

  • OtherFludeoxyglucose F-18

    Given FDG

  • ProcedurePositron Emission Tomography

    Undergo PET-CT

  • ProcedureComputed Tomography

    Undergo PET-CT

  • OtherQuestionnaire Administration

    Ancillary studies

Outcome measures

Primary

  • Change in mean standardized uptake value (SUV) changes in the heart

    Measured by sarcoidosis fludeoxyglucose F-18 (FDG) positron emission tomography (PET)-computed tomography (CT) scans.

    Time frame: Up to 30 months after radiotherapy

Secondary

  • Ability of pre- to post-radiotherapy SUV changes in the heart

    Time frame: Up to 30 months after radiotherapy

  • Overall survival

    Time frame: Up to 30 months after radiotherapy

  • Cardiac toxicity

    Time frame: Up to 30 months after radiotherapy

  • Cardiac toxicity judged to be secondary to radiotherapy by cardiologist and radiation oncologist

    Time frame: Up to 30 months after radiotherapy

  • Cardiac related death

    Time frame: Up to 30 months after radiotherapy

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Provide signed and dated informed consent form * Willing to comply with all study procedures and be available for the duration of the study * Male or female, aged \>= 18 * Life expectancy \>= 3 months as assessed by Radiation Oncologist * Mean heart dose estimated by Radiation Oncologist to be \>= 5 Gy (physics dose or biologically equivalent dose) * Pathologically proven (either histologic or cytologic) proven lung cancer or esophageal cancer * Planned radiation treatment course for management of lung or esophageal cancer \* Both standard and hypofractionation schedules are permitted Exclusion Criteria: * Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist * Palliative radiation doses defined as 20 Gy in 5 fractions

Study locations (1)

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Recruiting
Yevgeniy Vinogradskiy, MD · Contact
215-955-3605yevgeniy.vinogradskiy@jefferson.edu